首页
品牌
ELISA试剂盒
抗体抗原
公司新闻
技术文章
关于拜力
留言询价
产品资料
首页
>>>
产品目录
>>>
中国授权代理品牌
>>> 
Xcessbio
HCI-2509(SP2509),ReversibleLSD1Inhibitor.
点击看大图
如果您对该产品感兴趣的话,可以
产品名称:
HCI-2509(SP2509),ReversibleLSD1Inhibitor.
产品型号:
M60160-2s
产品展商:
其它品牌
产品文档:
无相关文档
简单介绍
HCI-2509(SP2509),ReversibleLSD1Inhibitor.
HCI-2509(SP2509),ReversibleLSD1Inhibitor.
的详细介绍
Product Information
Molecular Weight:
437.90
Formula:
C
19
H
20
ClN
3
O
5
S
Purity:
≥98%
CAS#:
1423715-09-6
Solubility:
DMSO up to 50 mM
Chemical Name:
(E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide
Storage:
Powder: 4
o
C 1 year. DMSO: 4
o
C 3 month; -20
o
C 1 year.
Biological Activity:
HCI-2509 (also named as SP2509 or LSD1-C12) is a highly potent, specific, and reversible Lysine Specific Demethylase-1 (LSD1) inhibitor. It inhibits LSD1 in biochemical assay with an IC50 ~13 nM, and has no activity against monoamine oxidase proteins MAO-A and MAO-B (>300 µM). HCI-2509 is a non-competitive inhibitor to bind LSD1, changes its solution dynamics in a manner distinct from TCP. It has minimal inhibition of CYPs and hERG, shows cellular activity against several cancer cell lines including endometrial, breast, colorectal, pancreatic, and prostate cancer (IC50 ~0.3-2.5 µM). HCI-2509 displayed sing-agent efficacy in multiple xenograft models and had good PK/PD relationship by using tumor histone H3K4 and H3K9 methylation. HCI-2509 serves as a very useful chemical probe to study the target
biolog
y of LSD1.
How to Use:
In vitro:
HCI-2509 was used at 1 µM in vitro.
In vivo:
HCI-2509 was administered through IP injection at 25-30 mg/kg once per day in xenografts models.
Reference:
1. Fiskus W, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. (2014) Leukemia. 28(11):2155-64.
2. Sorna V, et al. High-Throughput Virtual Screening Identifies Novel N'-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. (2013) J Med Chem. 56(23):9496-508.
3. Wiles ET, et al. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. (2013) PLoS One. 8(3):e59369.
4. Bret J. Stephens, et al.: Activity of the LSD1 inhibitor HCI-2509 in ER-negative breast cancer cells. (2012) AACR Chicago. Abstract 1045. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1.
5. Emily R, et al. Inhibition of LSD1 disrupts global EWS/ETS transcriptional function in Ewing sarcoma. (2014) AACR San Diego. Abstract 3679.
Products are for research use only. Not for human use.
产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!
相关产品
LibraryofEpigeneticcompounds LI30001-2
pNSC-CSB S10003
Neuronal-LSB3i S10002
Neural-LSB S10001
iPSC-TSPC S10005
iN-LSC S10004
ADCToxinMonomethylauristatinF(MMAF) T60002-10s
ADCToxinMonomethylauristatinE(MMAE) T60001-10s
SIRT1PolyclonalAntibody A90007-5
Phospho-HDAC4(Ser632)Antibody A90009-5
HistoneH4R3me2sPolyclonalAntibody A70026-5
HistoneH4R3me2aPolyclonalAntibody A70027-5
HistoneH4R3me1PolyclonalAntibody A70025-5
HistoneH3R2me2sPolyclonalAntibody A70030-5
HistoneH3R2me2aPolyclonalAntibody A70028-5
HistoneH3R2me1PolyclonalAntibody A70029-5
HistoneH3R26me1PolyclonalAntibody A70031-5
HistoneH3K9me3PolyclonalAntibody A70024-5
HistoneH3K9me2PolyclonalAntibody A70023-5
HistoneH3K9me1PolyclonalAntibody A70022-5
HistoneH3K79me3PolyclonalAntibody A70021-5
HistoneH3K79me2PolyclonalAntibody A70020-5
HistoneH3K79me1PolyclonalAntibody A70019-5
HistoneH3K4me3PolyclonalAntibody A70012-5
HistoneH3K4me2PolyclonalAntibody A70011-5
HistoneH3K36me3PolyclonalAntibody A70018-5
HistoneH3K36me2PolyclonalAntibody A70017-5
HistoneH3K36me1PolyclonalAntibody A70016-5
HistoneH3K27me3PolyclonalAntibody A70015-5
HistoneH3K27me2PolyclonalAntibody A70014-5
Copyright@ 2003-2024
上海拜力生物科技有限公司
版权所有
本公司网站所展示销售的产品仅供科研!
沪ICP备08023583号-12
沪公网安备 31011202007337号